Smith & Nephew plc (SNN)

GB — Healthcare Sector
Peers: SNNUF  CNMD  GKOS  ITGR  STE  OFIX  FMS 

Automate Your Wheel Strategy on SNN

With Tiblio's Option Bot, you can configure your own wheel strategy including SNN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SNN
  • Rev/Share 13.6707
  • Book/Share 12.6643
  • PB 2.7803
  • Debt/Equity 0.6239
  • CurrentRatio 3.0026
  • ROIC 0.0664

 

  • MktCap 15395834392.0
  • FreeCF/Share 1.8301
  • PFCF 19.2612
  • PE 31.152
  • Debt/Assets 0.323
  • DivYield 0.0214
  • ROE 0.0914

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade SNN Bernstein Outperform Market Perform -- $37.5 Oct. 14, 2025
Downgrade SNN HSBC Securities Buy Hold -- -- April 25, 2025
Downgrade SNN UBS Buy Neutral -- -- March 12, 2025

News

Smith & Nephew sees turnaround plan kicking in as profit grows
SNN
Published: February 25, 2025 by: Proactive Investors
Sentiment: Positive

Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the year to December 31, the medical equipment maker said Tuesday, aiding an 8.2% increase in trading profit to US$1.1 billion.

Read More
image for news Smith & Nephew sees turnaround plan kicking in as profit grows
UK's Smith+Nephew beats annual profit expectations
SNN
Published: February 25, 2025 by: Reuters
Sentiment: Positive

Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset the impact of weak demand from China.

Read More
image for news UK's Smith+Nephew beats annual profit expectations
Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand
SNN
Published: February 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

First in market to o ffe r A djustable T ensioning T echnology * for i nsertional A chilles r econstruction and l ateral a nkle i nstability r epair

Read More
image for news Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand

About Smith & Nephew plc (SNN)

  • IPO Date 1999-11-16
  • Website https://www.smith-nephew.com
  • Industry Medical - Devices
  • CEO Deepak S. Nath
  • Employees 17349
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.